Working towards a Group A Streptococcal vaccine: Report of a collaborative Trans-Tasman workshop
Abstract Group A Streptococcus (GAS) infections represent a major public health burden in both developing and developed countries. In Australia and New Zealand GAS associated diseases are serious problems in Indigenous populations and a major cause of health inequality. Political recognition of thes...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2014-06, Vol.32 (30), p.3713-3720 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3720 |
|---|---|
| container_issue | 30 |
| container_start_page | 3713 |
| container_title | Vaccine |
| container_volume | 32 |
| creator | Moreland, Nicole J Waddington, Claire S Williamson, Deborah A Sriskandan, Shiranee Smeesters, Pierre R Proft, Thomas Steer, Andrew C Walker, Mark J Baker, Edward N Baker, Michael G Lennon, Diana Dunbar, Rod Carapetis, Jonathan Fraser, John D |
| description | Abstract Group A Streptococcus (GAS) infections represent a major public health burden in both developing and developed countries. In Australia and New Zealand GAS associated diseases are serious problems in Indigenous populations and a major cause of health inequality. Political recognition of these inequalities is providing impetus for strategies that reduce GAS disease and the development of a GAS vaccine now has governmental support in both Australia and New Zealand. Accordingly, an expert workshop was convened in March 2013 to consider available data on GAS vaccines. M-protein based vaccines constructed from the hyper-variable N-terminal region (30-valent vaccine) or the conserved C-repeat domain (J8 vaccine) were reviewed together with vaccine candidates identified using multi high-throughput approaches. Performing a comprehensive assessment of regional GAS strain epidemiology, defining the immune correlates of protection, and the establishment of clinical trial sites were identified as critical activities for a Trans-Tasman vaccine development programme. |
| doi_str_mv | 10.1016/j.vaccine.2014.05.017 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1555017577</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X14006732</els_id><sourcerecordid>3330648741</sourcerecordid><originalsourceid>FETCH-LOGICAL-c676t-5261913cd731dd40d5e3a60f6747bd3cda8dbb60148abb95c92cf9c7cbaefc7f3</originalsourceid><addsrcrecordid>eNqFkl-L1DAUxYMo7jj6EZSACL605k-TtD6sLIuuwoLgjuhbTG9SzWynqUk7y357M0x1YV-EQCD87rnnnhuEnlNSUkLlm225NwB-cCUjtCqJKAlVD9CK1ooXTND6IVoRJquiouT7CXqS0pYQIjhtHqMTVtVcCUpW6Me3EK_98BNP4cZEm7DBFzHMIz7DV1N04xQgAJgeL93e4i9uDHHCocsohL43bYhm8nuHN9EMqdiYtDMDvsm66VcYn6JHnemTe7bca_T1w_vN-cfi8vPFp_OzywKkklMhmKQN5WAVp9ZWxArHjSSdVJVqbX43tW1bmUetTds2AhoGXQMKWuM6UB1fo9dH3TGG37NLk975BC77G1yYk6ZCiJyQUCqjL--h2zDHIbvLFK_yaSTLlDhSEENK0XV6jH5n4q2mRB9WoLd6CUUfVqCJ0LlBrnuxqM_tztl_VX8zz8CrBTApJ9vl1MCnO64WlRLZxRq9O3Iux7b3LuoE3g3grI8OJm2D_6-V03sK0PvB56bX7talu6l1Yproq8N_OXwXWhEiFWf8D06ivHI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1534534962</pqid></control><display><type>article</type><title>Working towards a Group A Streptococcal vaccine: Report of a collaborative Trans-Tasman workshop</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Moreland, Nicole J ; Waddington, Claire S ; Williamson, Deborah A ; Sriskandan, Shiranee ; Smeesters, Pierre R ; Proft, Thomas ; Steer, Andrew C ; Walker, Mark J ; Baker, Edward N ; Baker, Michael G ; Lennon, Diana ; Dunbar, Rod ; Carapetis, Jonathan ; Fraser, John D</creator><creatorcontrib>Moreland, Nicole J ; Waddington, Claire S ; Williamson, Deborah A ; Sriskandan, Shiranee ; Smeesters, Pierre R ; Proft, Thomas ; Steer, Andrew C ; Walker, Mark J ; Baker, Edward N ; Baker, Michael G ; Lennon, Diana ; Dunbar, Rod ; Carapetis, Jonathan ; Fraser, John D</creatorcontrib><description>Abstract Group A Streptococcus (GAS) infections represent a major public health burden in both developing and developed countries. In Australia and New Zealand GAS associated diseases are serious problems in Indigenous populations and a major cause of health inequality. Political recognition of these inequalities is providing impetus for strategies that reduce GAS disease and the development of a GAS vaccine now has governmental support in both Australia and New Zealand. Accordingly, an expert workshop was convened in March 2013 to consider available data on GAS vaccines. M-protein based vaccines constructed from the hyper-variable N-terminal region (30-valent vaccine) or the conserved C-repeat domain (J8 vaccine) were reviewed together with vaccine candidates identified using multi high-throughput approaches. Performing a comprehensive assessment of regional GAS strain epidemiology, defining the immune correlates of protection, and the establishment of clinical trial sites were identified as critical activities for a Trans-Tasman vaccine development programme.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2014.05.017</identifier><identifier>PMID: 24837510</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Allergy and Immunology ; Animals ; Applied microbiology ; Australia - epidemiology ; Bacteriology ; Biological and medical sciences ; Clinical Trials as Topic ; Developed countries ; Disease control ; Disease Models, Animal ; Epidemiology ; Fundamental and applied biological sciences. Psychology ; Healthcare Disparities ; Humans ; Immunization ; M protein ; Microbiology ; Miscellaneous ; Molecular Epidemiology ; Mortality ; Native peoples ; New Zealand - epidemiology ; Public health ; Rheumatic fever ; Streptococcal Infections - epidemiology ; Streptococcal Infections - prevention & control ; Streptococcal Vaccines - therapeutic use ; Streptococcus ; Streptococcus pyogenes ; Streptococcus pyogenes - pathogenicity ; Vaccine ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><ispartof>Vaccine, 2014-06, Vol.32 (30), p.3713-3720</ispartof><rights>2014</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2014. Published by Elsevier Ltd.. All rights reserved.</rights><rights>Copyright Elsevier Limited Jun 24, 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c676t-5261913cd731dd40d5e3a60f6747bd3cda8dbb60148abb95c92cf9c7cbaefc7f3</citedby><cites>FETCH-LOGICAL-c676t-5261913cd731dd40d5e3a60f6747bd3cda8dbb60148abb95c92cf9c7cbaefc7f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1534534962?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994,64384,64386,64388,72240</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28547545$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24837510$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moreland, Nicole J</creatorcontrib><creatorcontrib>Waddington, Claire S</creatorcontrib><creatorcontrib>Williamson, Deborah A</creatorcontrib><creatorcontrib>Sriskandan, Shiranee</creatorcontrib><creatorcontrib>Smeesters, Pierre R</creatorcontrib><creatorcontrib>Proft, Thomas</creatorcontrib><creatorcontrib>Steer, Andrew C</creatorcontrib><creatorcontrib>Walker, Mark J</creatorcontrib><creatorcontrib>Baker, Edward N</creatorcontrib><creatorcontrib>Baker, Michael G</creatorcontrib><creatorcontrib>Lennon, Diana</creatorcontrib><creatorcontrib>Dunbar, Rod</creatorcontrib><creatorcontrib>Carapetis, Jonathan</creatorcontrib><creatorcontrib>Fraser, John D</creatorcontrib><title>Working towards a Group A Streptococcal vaccine: Report of a collaborative Trans-Tasman workshop</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract Group A Streptococcus (GAS) infections represent a major public health burden in both developing and developed countries. In Australia and New Zealand GAS associated diseases are serious problems in Indigenous populations and a major cause of health inequality. Political recognition of these inequalities is providing impetus for strategies that reduce GAS disease and the development of a GAS vaccine now has governmental support in both Australia and New Zealand. Accordingly, an expert workshop was convened in March 2013 to consider available data on GAS vaccines. M-protein based vaccines constructed from the hyper-variable N-terminal region (30-valent vaccine) or the conserved C-repeat domain (J8 vaccine) were reviewed together with vaccine candidates identified using multi high-throughput approaches. Performing a comprehensive assessment of regional GAS strain epidemiology, defining the immune correlates of protection, and the establishment of clinical trial sites were identified as critical activities for a Trans-Tasman vaccine development programme.</description><subject>Allergy and Immunology</subject><subject>Animals</subject><subject>Applied microbiology</subject><subject>Australia - epidemiology</subject><subject>Bacteriology</subject><subject>Biological and medical sciences</subject><subject>Clinical Trials as Topic</subject><subject>Developed countries</subject><subject>Disease control</subject><subject>Disease Models, Animal</subject><subject>Epidemiology</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Healthcare Disparities</subject><subject>Humans</subject><subject>Immunization</subject><subject>M protein</subject><subject>Microbiology</subject><subject>Miscellaneous</subject><subject>Molecular Epidemiology</subject><subject>Mortality</subject><subject>Native peoples</subject><subject>New Zealand - epidemiology</subject><subject>Public health</subject><subject>Rheumatic fever</subject><subject>Streptococcal Infections - epidemiology</subject><subject>Streptococcal Infections - prevention & control</subject><subject>Streptococcal Vaccines - therapeutic use</subject><subject>Streptococcus</subject><subject>Streptococcus pyogenes</subject><subject>Streptococcus pyogenes - pathogenicity</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkl-L1DAUxYMo7jj6EZSACL605k-TtD6sLIuuwoLgjuhbTG9SzWynqUk7y357M0x1YV-EQCD87rnnnhuEnlNSUkLlm225NwB-cCUjtCqJKAlVD9CK1ooXTND6IVoRJquiouT7CXqS0pYQIjhtHqMTVtVcCUpW6Me3EK_98BNP4cZEm7DBFzHMIz7DV1N04xQgAJgeL93e4i9uDHHCocsohL43bYhm8nuHN9EMqdiYtDMDvsm66VcYn6JHnemTe7bca_T1w_vN-cfi8vPFp_OzywKkklMhmKQN5WAVp9ZWxArHjSSdVJVqbX43tW1bmUetTds2AhoGXQMKWuM6UB1fo9dH3TGG37NLk975BC77G1yYk6ZCiJyQUCqjL--h2zDHIbvLFK_yaSTLlDhSEENK0XV6jH5n4q2mRB9WoLd6CUUfVqCJ0LlBrnuxqM_tztl_VX8zz8CrBTApJ9vl1MCnO64WlRLZxRq9O3Iux7b3LuoE3g3grI8OJm2D_6-V03sK0PvB56bX7talu6l1Yproq8N_OXwXWhEiFWf8D06ivHI</recordid><startdate>20140624</startdate><enddate>20140624</enddate><creator>Moreland, Nicole J</creator><creator>Waddington, Claire S</creator><creator>Williamson, Deborah A</creator><creator>Sriskandan, Shiranee</creator><creator>Smeesters, Pierre R</creator><creator>Proft, Thomas</creator><creator>Steer, Andrew C</creator><creator>Walker, Mark J</creator><creator>Baker, Edward N</creator><creator>Baker, Michael G</creator><creator>Lennon, Diana</creator><creator>Dunbar, Rod</creator><creator>Carapetis, Jonathan</creator><creator>Fraser, John D</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>20140624</creationdate><title>Working towards a Group A Streptococcal vaccine: Report of a collaborative Trans-Tasman workshop</title><author>Moreland, Nicole J ; Waddington, Claire S ; Williamson, Deborah A ; Sriskandan, Shiranee ; Smeesters, Pierre R ; Proft, Thomas ; Steer, Andrew C ; Walker, Mark J ; Baker, Edward N ; Baker, Michael G ; Lennon, Diana ; Dunbar, Rod ; Carapetis, Jonathan ; Fraser, John D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c676t-5261913cd731dd40d5e3a60f6747bd3cda8dbb60148abb95c92cf9c7cbaefc7f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Allergy and Immunology</topic><topic>Animals</topic><topic>Applied microbiology</topic><topic>Australia - epidemiology</topic><topic>Bacteriology</topic><topic>Biological and medical sciences</topic><topic>Clinical Trials as Topic</topic><topic>Developed countries</topic><topic>Disease control</topic><topic>Disease Models, Animal</topic><topic>Epidemiology</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Healthcare Disparities</topic><topic>Humans</topic><topic>Immunization</topic><topic>M protein</topic><topic>Microbiology</topic><topic>Miscellaneous</topic><topic>Molecular Epidemiology</topic><topic>Mortality</topic><topic>Native peoples</topic><topic>New Zealand - epidemiology</topic><topic>Public health</topic><topic>Rheumatic fever</topic><topic>Streptococcal Infections - epidemiology</topic><topic>Streptococcal Infections - prevention & control</topic><topic>Streptococcal Vaccines - therapeutic use</topic><topic>Streptococcus</topic><topic>Streptococcus pyogenes</topic><topic>Streptococcus pyogenes - pathogenicity</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moreland, Nicole J</creatorcontrib><creatorcontrib>Waddington, Claire S</creatorcontrib><creatorcontrib>Williamson, Deborah A</creatorcontrib><creatorcontrib>Sriskandan, Shiranee</creatorcontrib><creatorcontrib>Smeesters, Pierre R</creatorcontrib><creatorcontrib>Proft, Thomas</creatorcontrib><creatorcontrib>Steer, Andrew C</creatorcontrib><creatorcontrib>Walker, Mark J</creatorcontrib><creatorcontrib>Baker, Edward N</creatorcontrib><creatorcontrib>Baker, Michael G</creatorcontrib><creatorcontrib>Lennon, Diana</creatorcontrib><creatorcontrib>Dunbar, Rod</creatorcontrib><creatorcontrib>Carapetis, Jonathan</creatorcontrib><creatorcontrib>Fraser, John D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moreland, Nicole J</au><au>Waddington, Claire S</au><au>Williamson, Deborah A</au><au>Sriskandan, Shiranee</au><au>Smeesters, Pierre R</au><au>Proft, Thomas</au><au>Steer, Andrew C</au><au>Walker, Mark J</au><au>Baker, Edward N</au><au>Baker, Michael G</au><au>Lennon, Diana</au><au>Dunbar, Rod</au><au>Carapetis, Jonathan</au><au>Fraser, John D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Working towards a Group A Streptococcal vaccine: Report of a collaborative Trans-Tasman workshop</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2014-06-24</date><risdate>2014</risdate><volume>32</volume><issue>30</issue><spage>3713</spage><epage>3720</epage><pages>3713-3720</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Abstract Group A Streptococcus (GAS) infections represent a major public health burden in both developing and developed countries. In Australia and New Zealand GAS associated diseases are serious problems in Indigenous populations and a major cause of health inequality. Political recognition of these inequalities is providing impetus for strategies that reduce GAS disease and the development of a GAS vaccine now has governmental support in both Australia and New Zealand. Accordingly, an expert workshop was convened in March 2013 to consider available data on GAS vaccines. M-protein based vaccines constructed from the hyper-variable N-terminal region (30-valent vaccine) or the conserved C-repeat domain (J8 vaccine) were reviewed together with vaccine candidates identified using multi high-throughput approaches. Performing a comprehensive assessment of regional GAS strain epidemiology, defining the immune correlates of protection, and the establishment of clinical trial sites were identified as critical activities for a Trans-Tasman vaccine development programme.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>24837510</pmid><doi>10.1016/j.vaccine.2014.05.017</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2014-06, Vol.32 (30), p.3713-3720 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1555017577 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
| subjects | Allergy and Immunology Animals Applied microbiology Australia - epidemiology Bacteriology Biological and medical sciences Clinical Trials as Topic Developed countries Disease control Disease Models, Animal Epidemiology Fundamental and applied biological sciences. Psychology Healthcare Disparities Humans Immunization M protein Microbiology Miscellaneous Molecular Epidemiology Mortality Native peoples New Zealand - epidemiology Public health Rheumatic fever Streptococcal Infections - epidemiology Streptococcal Infections - prevention & control Streptococcal Vaccines - therapeutic use Streptococcus Streptococcus pyogenes Streptococcus pyogenes - pathogenicity Vaccine Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) |
| title | Working towards a Group A Streptococcal vaccine: Report of a collaborative Trans-Tasman workshop |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T03%3A31%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Working%20towards%20a%20Group%20A%20Streptococcal%20vaccine:%20Report%20of%20a%20collaborative%20Trans-Tasman%20workshop&rft.jtitle=Vaccine&rft.au=Moreland,%20Nicole%20J&rft.date=2014-06-24&rft.volume=32&rft.issue=30&rft.spage=3713&rft.epage=3720&rft.pages=3713-3720&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2014.05.017&rft_dat=%3Cproquest_cross%3E3330648741%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1534534962&rft_id=info:pmid/24837510&rft_els_id=S0264410X14006732&rfr_iscdi=true |